217 related articles for article (PubMed ID: 27870568)
21. Comparison of Vital Status, Cause of Death, and Follow-Up after Hematopoietic Cell Transplantation in Linked Center for International Blood and Marrow Transplant Research and California Cancer Registry Data, 1991 to 2018.
Valcarcel B; Schonfeld SJ; Meyer CL; Brunson A; Cooley JJP; Abrahão R; Wun T; Auletta JJ; Gadalla SM; Engels E; Albert PS; Spellman SR; Rizzo JD; Shaw BE; Muffly L; Keegan THM; Morton LM
Transplant Cell Ther; 2024 Feb; 30(2):239.e1-239.e11. PubMed ID: 37981238
[TBL] [Abstract][Full Text] [Related]
22. Gut Microbiota Predict Pulmonary Infiltrates after Allogeneic Hematopoietic Cell Transplantation.
Harris B; Morjaria SM; Littmann ER; Geyer AI; Stover DE; Barker JN; Giralt SA; Taur Y; Pamer EG
Am J Respir Crit Care Med; 2016 Aug; 194(4):450-63. PubMed ID: 26886180
[TBL] [Abstract][Full Text] [Related]
23. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies.
Naik S; Martinez C; Leung K; Sasa G; Nguyen NY; Wu MF; Gottschalk S; Brenner M; Heslop H; Krance R
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1266-72. PubMed ID: 25765555
[TBL] [Abstract][Full Text] [Related]
24. Chronic kidney disease in long-term survivors of myeloablative allogeneic haematopoietic cell transplantation: prevalence and risk factors.
Ando M; Ohashi K; Akiyama H; Sakamaki H; Morito T; Tsuchiya K; Nitta K
Nephrol Dial Transplant; 2010 Jan; 25(1):278-82. PubMed ID: 19762604
[TBL] [Abstract][Full Text] [Related]
25. Late congestive heart failure after hematopoietic cell transplantation.
Armenian SH; Sun CL; Francisco L; Steinberger J; Kurian S; Wong FL; Sharp J; Sposto R; Forman SJ; Bhatia S
J Clin Oncol; 2008 Dec; 26(34):5537-43. PubMed ID: 18809605
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for 30-day hospital readmission following myeloablative allogeneic hematopoietic cell transplantation (allo-HCT).
Bejanyan N; Bolwell BJ; Lazaryan A; Rybicki L; Tench S; Duong H; Andresen S; Sobecks R; Dean R; Pohlman B; Kalaycio M; Copelan EA
Biol Blood Marrow Transplant; 2012 Jun; 18(6):874-80. PubMed ID: 22040844
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor.
Robin M; Porcher R; De Castro Araujo R; de Latour RP; Devergie A; Rocha V; Larghero J; Adès L; Ribaud P; Mary JY; Socié G
Biol Blood Marrow Transplant; 2007 Nov; 13(11):1304-12. PubMed ID: 17950917
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of readmission in children receiving allogeneic hematopoietic stem cell transplantation: an institutional experience.
Jaing TH; Tsay PK; Yang CP; Hung IJ; Wen YC; Tseng CK
Transplant Proc; 2008 Dec; 40(10):3643-5. PubMed ID: 19100457
[TBL] [Abstract][Full Text] [Related]
29. Outcome of Second Allogeneic Hematopoietic Cell Transplantation after Relapse of Myeloid Malignancies following Allogeneic Hematopoietic Cell Transplantation: A Retrospective Cohort on Behalf of the Grupo Español de Trasplante Hematopoyetico.
Orti G; Sanz J; Bermudez A; Caballero D; Martinez C; Sierra J; Cabrera Marin JR; Espigado I; Solano C; Ferrà C; García-Noblejas A; Jimenez S; Sampol A; Yañez L; García-Gutiérrez V; Pascual MJ; Jurado M; Moraleda JM; Valcarcel D; Sanz MA; Carreras E; Duarte RF
Biol Blood Marrow Transplant; 2016 Mar; 22(3):584-8. PubMed ID: 26631751
[TBL] [Abstract][Full Text] [Related]
30. Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.
El-Jawahri A; LeBlanc T; VanDusen H; Traeger L; Greer JA; Pirl WF; Jackson VA; Telles J; Rhodes A; Spitzer TR; McAfee S; Chen YA; Lee SS; Temel JS
JAMA; 2016 Nov; 316(20):2094-2103. PubMed ID: 27893130
[TBL] [Abstract][Full Text] [Related]
31. Linking the Center for International Blood and Marrow Transplant Research Registry to the California Cancer Registry and California Hospital Patient Discharge Data.
Keegan THM; Brunson A; Cooley JJP; Schonfeld SJ; Meyer CL; Valcarcel B; Abrahao R; Wun T; Auletta J; Muffly L; Morton LM
Transplant Cell Ther; 2022 Dec; 28(12):859.e1-859.e10. PubMed ID: 36174935
[TBL] [Abstract][Full Text] [Related]
32. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study.
Bhatia S; Francisco L; Carter A; Sun CL; Baker KS; Gurney JG; McGlave PB; Nademanee A; O'Donnell M; Ramsay NK; Robison LL; Snyder D; Stein A; Forman SJ; Weisdorf DJ
Blood; 2007 Nov; 110(10):3784-92. PubMed ID: 17671231
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular Function in Long-Term Hematopoietic Cell Transplantation Survivors.
Armenian SH; Horak D; Scott JM; Mills G; Siyahian A; Berano Teh J; Douglas PS; Forman SJ; Bhatia S; Jones LW
Biol Blood Marrow Transplant; 2017 Apr; 23(4):700-705. PubMed ID: 28065839
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of lung transplantation after allogeneic hematopoietic stem cell transplantation.
Cheng GS; Edelman JD; Madtes DK; Martin PJ; Flowers ME
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1169-75. PubMed ID: 24727334
[TBL] [Abstract][Full Text] [Related]
35. Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.
Brunner AM; Kim HT; Coughlin E; Alyea EP; Armand P; Ballen KK; Cutler C; Dey BR; Glotzbecker B; Koreth J; McAfee SL; Spitzer TR; Soiffer RJ; Antin JH; Ho VT; Chen YB
Biol Blood Marrow Transplant; 2013 Sep; 19(9):1374-80. PubMed ID: 23791626
[TBL] [Abstract][Full Text] [Related]
36. Decline in the Use of Surgical Biopsy for Diagnosis of Pulmonary Disease in Hematopoietic Cell Transplantation Recipients in an Era of Improved Diagnostics and Empirical Therapy.
Cheng GS; Stednick ZJ; Madtes DK; Boeckh M; McDonald GB; Pergam SA
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2243-2249. PubMed ID: 27590103
[TBL] [Abstract][Full Text] [Related]
37. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant.
Wood W; Deal A; Whitley J; Sharf A; Serody J; Gabriel D; Shea T
Pediatr Blood Cancer; 2011 Sep; 57(3):499-505. PubMed ID: 21384538
[TBL] [Abstract][Full Text] [Related]
39. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older.
Wallen H; Gooley TA; Deeg HJ; Pagel JM; Press OW; Appelbaum FR; Storb R; Gopal AK
J Clin Oncol; 2005 May; 23(15):3439-46. PubMed ID: 15824415
[TBL] [Abstract][Full Text] [Related]
40. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
